Vertex Pharmaceuticals Inc
NASDAQ:VRTX

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Watchlist
Price: 441.36 USD 0.56% Market Closed
Market Cap: 112B USD

Operating Margin

38.7%
Current
Declining
by 4.3%
vs 3-y average of 43%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
38.7%
=
Operating Income
$4.5B
/
Revenue
$11.7B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
38.7%
=
Operating Income
$4.5B
/
Revenue
$11.7B

Peer Comparison

Country Company Market Cap Operating
Margin
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Merck & Co Inc
NYSE:MRK
270.7B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
112.5B USD
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
AU
CSL Ltd
ASX:CSL
85B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.4B EUR
Loading...
No Stocks Found

Market Distribution

Higher than 93% of companies in the United States of America
Percentile
93rd
Based on 10 501 companies
93rd percentile
38.7%
Low
-1 924 693.3% — 3.4%
Typical Range
3.4% — 17.8%
High
17.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -1 924 693.3%
30th Percentile 3.4%
Median 10%
70th Percentile 17.8%
Max 1 032 600%

Vertex Pharmaceuticals Inc
Glance View

In the bustling landscape of biotechnology, Vertex Pharmaceuticals Inc. stands out as a dynamic powerhouse that has deftly carved a niche in the complex domain of genetic therapies. Founded in 1989, the company initially embarked on a mission to revolutionize drug discovery through a cutting-edge rational drug design approach. Armed with an innovative spirit and a focus on niche markets, Vertex turned its attention towards cystic fibrosis—a life-shortening genetic disorder affecting the lungs and digestive system. The company’s breakthrough came with the development and approval of the first therapies that address the underlying cause of cystic fibrosis, rather than just alleviating symptoms. These products, including Kalydeco and Trikafta, have repositioned Vertex from a scrappy biotech upstart to a dominating force in the drug market as these life-changing treatments not only improve patient outcomes but also command premium pricing. Vertex’s business model brilliantly capitalizes on its deep investment in research and development, allowing it to maintain a robust pipeline that promises ongoing growth. By channeling a substantial portion of its revenue back into R&D, Vertex seeks to extend its therapeutic successes beyond cystic fibrosis into other serious diseases with high unmet needs, such as sickle cell disease and beta-thalassemia. This strategic reinvestment supports a cyclical framework of innovation—capitalize on current successes while laying down the groundwork for future therapies. With a singular focus on specialty drugs that target specific genetic mutations or pathways, Vertex not only thrives on the immediate financial returns of its blockbuster drugs but continually invests in scientifically ambitious endeavors, thus reinforcing its status as a leader in the precision medicine sector.

VRTX Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
38.7%
=
Operating Income
$4.5B
/
Revenue
$11.7B
What is Vertex Pharmaceuticals Inc's current Operating Margin?

The current Operating Margin for Vertex Pharmaceuticals Inc is 38.7%, which is below its 3-year median of 43%.

How has Operating Margin changed over time?

Over the last 3 years, Vertex Pharmaceuticals Inc’s Operating Margin has decreased from 48.9% to 38.7%. During this period, it reached a low of 37.9% on Mar 31, 2025 and a high of 49.7% on Dec 31, 2022.

Back to Top